{"id":10703,"date":"2013-10-01T16:33:00","date_gmt":"2013-10-01T16:33:00","guid":{"rendered":"https:\/\/web.uri.edu\/pharmacy\/?page_id=10703"},"modified":"2013-10-01T16:33:00","modified_gmt":"2013-10-01T16:33:00","slug":"publications","status":"publish","type":"page","link":"https:\/\/web.uri.edu\/pharmacy\/research\/laplante\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"

Dr. LaPlante’s Research Program<\/strong><\/a><\/h1>\n

Kerry L. LaPlante, B.S. Pharm.D.<\/a><\/h3>\n

The Outcome and Outreach Research Team is Located in Suite 395J on Level 3 of Avedisian Hall<\/a><\/strong>
\n The Laboratory Research Team is Located in Lab Module 390 on Level 3 of Avedisian Hall<\/a><\/strong><\/p>\n

\n
Overview<\/a> Research<\/a> Publications<\/a> Research Team<\/a> Contact<\/a><\/div>\n
\n

Publications<\/h3>\n

In vitro Research Program – Pharmacodynamics\/Biofilm\/Catheter Lock Therapy<\/strong>
\n1. LaPlante KL, Woodmansee SB, Mermel LA. Compatibility and stability of telavancin and vancomycin in heparin or sodium citrate antibiotic lock solutions. Am J Health Syst Pharm. 2012 Aug 15;69(16):1405-9.
\n2. Li E, Greenberg PB, Tseng V, Woodmansee SB, Caffrey AR, Wu W, Friedman PD, LaPlante KL. In Vitro Coagulation Effects of ophthalmic doses of bevacizumab. J Ocul Pharmacol Th. 2012 Jun;28(3):219-21.
\n3. LaPlante KL, Sarkisian SA, Woodmansee SB, Rowley DC, Seeram N. Effects of Cranberry Extracts on Growth and Biofilm Production of Escherichia coli and Staphylococcus species. Phytother Res. 2012 Feb 1.
\n4. McConeghy K, and LaPlante KL, In vitro activity of tigecycline in combination with gentamicin against biofilm forming Staphylococcus aureus; Diagn Microbiol Infect Dis. 2010 Sep;68(1):1-6.
\n5. LaPlante KL, Sakoulas G, Evaluating aztreonam and ceftazidime activity against Escherichia coli in combination with daptomycin, linezolid or vancomycin in an in vitro pharmacodynamic model; Antimicrob Agents Chemother. 2009 Oct;53(10):4549-55
\n6. LaPlante KL, Woodmansee, S, Activity of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming MRSA in an experimental model of endocarditis Antimicrob Agents Chemother. 2009 Sep;53(9):3880-6.
\n7. LaPlante KL Mermel LA. In vitro activity of Telavancin and Vancomycin against Biofilm-Producing Staphylococcus aureus, S. epidermidis and Enterococcus faecalis; Antimicrob Agents Chemother. 2009 Jul;53(7):3166-9.
\n8. LaPlante KL, Rybak MJ. Andes D, Craig WA. Community Associated-Methicillin Resistant Staphylococcus aureus isolates versus Daptomycin, Clindamycin, Doxycycline, Linezolid and Trimethoprim\/Sulfamethoxazole in an in vitro Pharmacodynamic model. Antimicrob Agents Chemother. 2008 Jun;52(6):2156-62.
\n9. LaPlante KL Mermel LA. In Vitro Activity of Daptomycin and Vancomycin Lock Solutions on Staphylococcal Biofilms in a Central Venous Catheter Model. Nephrol. Dial. Transplant. 22: 2239-2246; 2007
\n10. LaPlante KL, Rybak MJ, Tsuji B, Lodise, T, Kaatz GW, Fluoroquinolone Resistance in Streptococcus pneumoniae, Area Under the Curve: Minimum Inhibitory Concentration Ratio and the Probability of Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Antimicrob Agents Chemother. 2007 Apr;51(4):1315-20.
\n11. LaPlante KL, Rybak MJ, Amjad A, Kaatz GW. Antimicrobial Susceptibility and Staphylococcal Chromosomal Cassette mec Type in Community- and Hospital-Associated Methicillin-Resistant Staphylococcus aureus. Pharmacotherapy. 2007 Jan;27(1):3-10.
\n12. LaPlante KL, In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2007 Apr;57(4):413-8.
\n13. LaPlante KL, Rybak MJ, Leuthner KL, Chin JN Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob Agents Chemother. 2006 Apr;50(4):1298-303.
\n14. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72.
\n15. LaPlante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn Microbiol Infect Dis. 2004 Oct;50(2):125-30.
\nAntimicrobial Stewardship and Outcomes Research Program<\/strong>
\n16. Caffrey AR, Morrill HJ, Puzniak LA, LaPlante KL. Comparative Effectiveness of Linezolid and Vancomycin among a National Veterans Affairs Cohort with Methicillin-Resistant Staphylococcus aureus Pneumonia. Pharmacotherapy, in press.
\n17. Alshammari TM, LarratEP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL. Fluoroquinolone Use and Hepatotoxicity Risk: A Case-Control Study Using the National Veterans Affairs Database. American Journal of Health-System Pharmacy 2013, in press.
\n18. Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother. 2013 Jun 24.
\n19. Caffrey AR, LaPlante KL. Changing Epidemiology of Methicillin-Resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002-2009. Infection. 2012 Jun;40(3):291-72011
\n20. Caffrey AR, Woodmansee SB, Crandall N. Tibert C, Fielding C, Mikolich DJ, Vezeridis MP, LaPlante KL. Low Adherence to Outpatient Pre-Operative Methicillin-Resistant Staphylococcus aureus Decolonization Therapy. Infect Control Hosp Epidemiol. 2011 Sep;32(9):930-2.
\n21. Caffrey AR, Quilliam BJ, LaPlante KL. Risk factors associated with mupirocin resistance in methicillin-resistant Staphylococcus aureus. Journal of Hospital Infection. 2010 Nov;76(3):206-10.
\n22. Caffrey AR, Quilliam BJ, LaPlante KL. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus Antimicrobial Agents and Chemotherapy. Antimicrob Agents Chemother. 2010 Oct;54(10):4394-400.
\n23. LaPlante KL, Mersfelder TL, Ward KE, Quilliam, BJ. Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. Pharmacotherapy. 2008 Jan;28(1):82-9.
\nDrug Discovery Collaborations<\/strong>
\n24. Sarkisian SA, Janssen MJ, Matta H, Henry GE, LaPlante KL, Rowley DC. Inhibition of Bacterial Growth and Biofilm Production by Constituents from Hypericum spp. Phytother Res. 2011 Dec 15.
\n25. Socha A, N Tan; KL LaPlante, J Sello. Diversity-Oriented Synthesis of Cyclic Acyldepsipeptides Leads to the Discovery of a Potent Antibacterial Agent. Bioorg Med Chem Lett. 2010 Oct 15;18(20):7193-202.
\n26. Socha A, LaPlante KL, Russell D, Rowley DR. Structure Activity Studies of Echinomycin Antibiotics against Drug-Resistant and Biofilm-Forming Staphylococcus aureus and Enterococcus faecalis. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1504-7.
\n27. Socha A, LaPlante KL, Rowley DR, New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates.
\nBioorg Med Chem. 2006 Dec 15;14(24):8446-54.
\nReview Articles Published in Peer Reviewed Journals<\/strong>
\n28. McConeghy K, Mikolich D and LaPlante KL, A Review of Agents for the Decolonization of Methicillin-Resistant Staphylococcus aureus; Pharmacotherapy. 2009 Mar;29(3):263-80. Review.
\n*Recognized as the sixth most downloaded paper in Pharmacotherapy in 2009
\n*20th Most Significant Publication in Infectious Diseases Pharmacotherapy in 2010
\n*Top ten paper in 2011
\n29. DePestel DD, Benninger M, Danziger L, LaPlante KL, May C, Luskin A, Pichichero M, Hadley JA. Cephalosporin Use in the Treatment of Penicillin-Allergic Patients; J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):530-40. Review.
\n30. Attwood RJ, LaPlante KL. Telavancin, a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm. 2007 Nov 15;64(22):2335-48. Review.
\n31. Ward KE, Mersfelder TL, LaPlante KL. Oritavancin; an investigational glycopeptide antibiotic.
\nExpert Opin Investig Drugs. 2006 Apr;15(4):417-29. Review.
\n32. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review.
\nPharmacotherapy. 2005 Jan;25(1):74-85. Review.
\n*Recognized as the #1 most downloaded paper in Pharmacotherapy in 2005
\n33. LaPlante KL, Rybak, MJ. Daptomycin – a novel antibiotic against Gram-positive pathogens.
\nExpert Opin Pharmacother. 2004 Nov;5(11):2321-31. Review.
\n34. Tedesco KL, Rybak MJ. Daptomycin; Drug Review. Pharmacotherapy 2004;24 (1):41-57. Review.
\nBook Chapters<\/strong>
\n35. Rybak MJ, LaPlante KL, Aeschlimann JR. Use of Laboratory Tests to Direct Antimicrobial Therapy; Pharmacotherapy: A Pathophysiologic Approach; 9th edition. 2012. (in press)
\n36. Rybak MJ, Aeschlimann J, LaPlante KL. Use of Laboratory Tests to Direct Antimicrobial Therapy; Pharmacotherapy: A Pathophysiologic Approach; 8th Edition. Posey LM, Matzke GR, DiPiro JT, Yee GC, Talbert RL, Wells BG Eds. McGraw-Hill Medical, ISBN 9780071784993. 2011.
\n37. Rybak MJ, LaPlante KL, Aeschlimann JR. Use of Laboratory Tests to Direct Antimicrobial Therapy; Pharmacotherapy: A Pathophysiologic Approach; 7th Edition. Posey LM, Matzke GR, DiPiro JT, Yee GC, Talbert RL, Wells BG Eds. McGraw-Hill Medical, 2008.
\n38. LaPlante KL, Rybak MJ. Daptomycin; Antimicrobial Therapy and Vaccines Volume II; Second Edition. Yu VL, Weber R, & Raoult D, Eds. ESun Technologies, ISBN 0-9700027-5-0. 2007.<\/p>\n

\n\u00a0<\/strong>\n<\/div>\n

 \n<\/p><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Dr. LaPlante’s Research Program Kerry L. LaPlante, B.S. Pharm.D. The Outcome and Outreach Research Team is Located in Suite 395J on Level 3 of Avedisian Hall The Laboratory Research Team is Located in Lab Module 390 on Level 3 of Avedisian Hall Overview Research Publications Research Team Contact Publications In vitro Research Program – Pharmacodynamics\/Biofilm\/Catheter […]<\/p>\n","protected":false},"author":639,"featured_media":0,"parent":5236,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-twocol.php","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-10703","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/pages\/10703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/users\/639"}],"replies":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/comments?post=10703"}],"version-history":[{"count":0,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/pages\/10703\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/pages\/5236"}],"wp:attachment":[{"href":"https:\/\/web.uri.edu\/pharmacy\/wp-json\/wp\/v2\/media?parent=10703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}